Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma.

Weinstein, Alyona; Gordon, Ruth-Ann; Kasler, Mary Kate; Burke, Matthew; Ranjan, Smita; Hodgetts, Jackie; Reed, Vanessa; Shames, Yelena; Prempeh-Keteku, Nana; Lingard, Karla

Weinstein, Alyona; Gordon, Ruth-Ann; Kasler, Mary Kate; Burke, Matthew; Ranjan, Smita; Hodgetts, Jackie; Reed, Vanessa; Shames, Yelena; Prempeh-Keteku, Nana; Lingard, Karla.

Afiliación

Weinstein A; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Gordon RA; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Kasler MK; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Burke M; Yale University School of Medicine, New Haven, Connecticut, USA.
Ranjan S; University of Louisville, Louisville, Kentucky, USA.
Hodgetts J; Christie Hospital, Manchester, UK.
Reed V; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Shames Y; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Prempeh-Keteku N; Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Lingard K; Royal Marsden Hospital, London, UK.

J Adv Pract Oncol ; 8(1): 58-72, 2017.

Article en En | MEDLINE | ID: mdl-29900017

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Guideline / Risk_factors_studies Idioma: En Revista: J Adv Pract Oncol Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google